Hillsdale Investment Management Inc. Has $1.02 Million Stake in Chemed Corporation $CHE

Hillsdale Investment Management Inc. raised its stake in Chemed Corporation (NYSE:CHE) by 90.9% during the second quarter, HoldingsChannel.com reports. The fund owned 2,100 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Chemed were worth $1,023,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SVB Wealth LLC acquired a new stake in shares of Chemed in the 1st quarter valued at $30,000. WPG Advisers LLC acquired a new stake in shares of Chemed during the 1st quarter worth about $32,000. Creekmur Asset Management LLC bought a new position in Chemed during the 2nd quarter valued at about $28,000. Parkside Financial Bank & Trust boosted its position in Chemed by 86.3% in the second quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after buying an additional 44 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its position in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after buying an additional 76 shares in the last quarter. 95.85% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 3,000 shares of Chemed stock in a transaction on Friday, September 26th. The shares were sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the sale, the chief executive officer owned 96,197 shares of the company’s stock, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Patrick P. Grace sold 150 shares of the company’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total transaction of $69,508.50. Following the sale, the director owned 3,397 shares of the company’s stock, valued at $1,574,135.83. The trade was a 4.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.29% of the company’s stock.

Chemed Stock Up 2.9%

CHE stock opened at $441.83 on Friday. Chemed Corporation has a twelve month low of $408.42 and a twelve month high of $623.60. The company has a market cap of $6.26 billion, a P/E ratio of 23.36, a PEG ratio of 2.69 and a beta of 0.43. The business has a fifty day moving average of $441.71 and a 200-day moving average of $478.55.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.39 by ($0.12). The firm had revenue of $624.90 million during the quarter, compared to the consensus estimate of $626.04 million. Chemed had a net margin of 11.02% and a return on equity of 25.89%. Chemed’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities research analysts anticipate that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Monday, November 17th will be given a dividend of $0.60 per share. The ex-dividend date is Monday, November 17th. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. Chemed’s payout ratio is currently 12.69%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on CHE shares. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and raised their price objective for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Oppenheimer reduced their price target on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Bank of America decreased their price objective on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Finally, Royal Bank Of Canada dropped their target price on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $574.25.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.